Title: Staphylococcus saprophyticus: Which beta-lactam? - ScienceDirect
Headings: Staphylococcus saprophyticus
: Which beta-lactam?

International Journal of Infectious Diseases
Short Communication
Staphylococcus saprophyticus: Which beta-lactam?
Highlights
Abstract
Background
Methods
Results
Conclusions
Keywords
Introduction
Methods
Results
Discussion
Conflict of interest/funding
References

Content: According to this rule, all of the MSSS isolates included in this study must be interpreted as susceptible to ceftriaxone. Considering the ceftriaxone MIC values observed for MSSS isolates, this raises questions about a lower susceptibility of MSSS to cephalosporins. Recommendations for the treatment of acute pyelonephritis often include an initial intravenous treatment with ceftriaxone ( Gupta et al., 2011 ). Concurrently, the MIC values of ciprofloxacin were ≤1 μg/ml for all MSSS isolates included in the study, suggesting the possibility of using fluoroquinolones instead of ceftriaxone in pyelonephritis due to MSSS. In this context, these data suggest that treatment with ciprofloxacin should be considered instead. The natural resistance of S. saprophyticus to the antibiotics recommended for the treatment of acute cystitis, such as fosfomycin trometamol, and the high ceftriaxone MIC values for MSSS isolates, complicate the handling of UTIs associated with S. saprophyticus. This study suggests that early results (Gram-positive cocci on Gram staining examination and leukocyte count >104 /ml) indicating uncomplicated S. saprophyticus cystitis in urine sampled from young wome